BioCentury
ARTICLE | Clinical News

Neotrofin leteprinim (AIT-082): Began Phase II study

April 2, 2001 7:00 AM UTC

NeoTherapeutics Inc. (NEOT), Irvine, Calif. Product: Neotrofin leteprinim (AIT-082) Business: Neurological Therapeutic category: Growth factor, Nerve regeneration Target: Neurotrophic factors Descript...